PROBLEM TO BE SOLVED: To provide a therapeutic agent for hepatitis, particularly a therapeutic agent for non-alcoholic steatohepatitis and a therapeutic agent for acute hepatitis.SOLUTION: The invention relates to adipose tissue-derived interstitial cell groups having an excellent inflammation inhibitory effect, fibrosis inhibitory effect, metabolic abnormality improving effect (particularly fatty acid metabolism improving effect), and hepatopathy improving effect, wherein the ratio of CD105 positive cells is 0.1-40.0% and/or the ratio of CD45 positive cells is 0.1-20.0% to all the cells and to a therapeutic agent for a non-alcoholic steatohepatitis, a therapeutic agent for acute hepatitis, and a therapeutic agent for metabolic abnormality containing the cell groups as an active ingredient.SELECTED DRAWING: NoneCOPYRIGHT: (C)2016,JPO&INPIT【課題】肝炎治療剤、特に、非アルコール性脂肪性肝炎治療剤及び急性肝炎治療剤の提供。【解決手段】優れた炎症抑制効果、線維化抑制効果、代謝異常改善効果(特に、脂肪酸代謝改善効果)及び肝障害の改善効果を有する、全細胞に対してCD105陽性細胞の割合が0.1~40.0%及び/又はCD45陽性細胞の割合が0.1~20.0%である脂肪組織由来間質細胞群、及び該細胞群を有効成分とする非アルコール性脂肪性肝炎治療剤及び急性肝炎治療剤、代謝異常治療剤。【選択図】なし
